2012
DOI: 10.1016/s0016-5085(12)63650-6
|View full text |Cite
|
Sign up to set email alerts
|

1022 Mitochondria-Targeting Antioxidant Attenuates Carbon Tetracholride-Induced Liver Fibrosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(13 citation statements)
references
References 0 publications
0
13
0
Order By: Relevance
“…Studies have demonstrated that SAC improved liver disease via regulation of the peroxisomal proliferator activator receptor α (PPAR-α), sterol regulatory element binding protein 1c (SREBP-1c), serum adiponectin levels, liver MDA, reactive oxygen species (ROS) content, serum ALT, serum AST, GSH content, GSH-Px and CAT activities, and the inhibition of lipolysis. Additionally, SAC can significantly inhibit N-nitrosodiethylamine (NDEA)-induced hepatocarcinogenesis [4,36,37,38]. We further analyzed the SAC content of EA, BA, and WS where, from the data, it was found that SAC only appeared in BA (497.58 ± 43.78 μg/g, Table 1).…”
Section: Discussionmentioning
confidence: 99%
“…Studies have demonstrated that SAC improved liver disease via regulation of the peroxisomal proliferator activator receptor α (PPAR-α), sterol regulatory element binding protein 1c (SREBP-1c), serum adiponectin levels, liver MDA, reactive oxygen species (ROS) content, serum ALT, serum AST, GSH content, GSH-Px and CAT activities, and the inhibition of lipolysis. Additionally, SAC can significantly inhibit N-nitrosodiethylamine (NDEA)-induced hepatocarcinogenesis [4,36,37,38]. We further analyzed the SAC content of EA, BA, and WS where, from the data, it was found that SAC only appeared in BA (497.58 ± 43.78 μg/g, Table 1).…”
Section: Discussionmentioning
confidence: 99%
“…Mitoquinone (MitoQ)—a mitochondria‐targeted anti‐oxidant—consists of co‐enzyme Q10 and a TPP cation that can easily accumulate several 100‐fold within the mitochondria, thereby making it more powerful than untargeted anti‐oxidants in preventing mitochondrial oxidative damage . In vitro and in vivo studies have demonstrated that MitoQ is protective against many oxidative damage‐related diseases . In addition, daily oral doses of 40 or 80 mg MitoQ have been shown to protect against liver damage in hepatitis C patients and can be safely administered to Parkinson's disease patients for up to 1 year .…”
Section: Introductionmentioning
confidence: 99%
“…25 In vitro and in vivo studies have demonstrated that MitoQ is protective against many oxidative damage-related diseases. [26][27][28][29][30][31][32][33] In addition, daily oral doses of 40 or 80 mg MitoQ have been shown to protect against liver damage in hepatitis C patients 34 and can be safely administered to Parkinson's disease patients for up to 1 year. 35 There is evidence that the protective effect of MitoQ is partially mediated by the modulation of mitochondrial dynamics, mitophagy and Nrf2 signalling.…”
Section: Introductionmentioning
confidence: 99%
“…155 In mice experiments, mitoQ showed inhibition of HSCs activation and transforming growth factor-beta 1 expression, both key factors in hepatic fibrosis. 156,157 Targeting Farnesoid X Receptor…”
Section: Mitoqmentioning
confidence: 99%